SCHEMBL5082218

SCHEMBL5082218

CCCCC(=C(c1ccc(OC(=O)C(C)(C)C)cc1)c1ccc(OC(=O)C(C)(C)C)cc1)c1ccc(OCCN2CCCCC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB1 P20618 7/20 0.64
PSMB5 P28074 6/20 0.64
PSMB2 P49721 3/20 0.64
THRB P10828 4/20 0.59
ALDH1A1 P00352 2/20 0.59
LMNA P02545 2/20 0.59
CYP1A2 P05177 1/20 0.59
CHRM2 P08172 1/20 0.59
CHRM4 P08173 1/20 0.59
CHRM5 P08912 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
ADRA2C P18825 1/20 0.59
DRD4 P21917 1/20 0.59
ACHE P22303 1/20 0.59
SLC6A2 P23975 1/20 0.59
HRH2 P25021 1/20 0.59
HTR2A P28223 1/20 0.59
ADRA1A P35348 1/20 0.59
HRH1 P35367 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5075819 0.86 ESR1 (0.74) PSMB1PSMB5PSMB2THRBALDH1A1
SCHEMBL5075243 0.86 ESR1 (0.74) PSMB1PSMB5PSMB2THRBALDH1A1
SCHEMBL5075011 0.86 ESR1 (0.74) PSMB1PSMB5PSMB2THRBALDH1A1
SCHEMBL5136332 0.84 PSMB1 (0.89) PSMB1PSMB5PSMB2ESR1ESRRG
SCHEMBL5073334 0.82 ESRRB (0.60) PSMB1PSMB5LMNACYP1A2CHRM2
SCHEMBL24354598 0.82 ESR1 (0.82) PSMB1PSMB5PSMB2ESR1ESRRG
SCHEMBL14539097 0.82 ESR1 (0.82) PSMB1PSMB5PSMB2ESR1ESRRG
SCHEMBL5075271 0.81 ESR1 (0.66) ESR1ESRRG
SCHEMBL5075219 0.80 PSMB1 (0.82) PSMB1PSMB5PSMB2ESR1ESRRG
SCHEMBL5075009 0.80 PSMB1 (0.82) PSMB1PSMB5PSMB2ESR1ESRRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255089-A1 Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives SMITHKLINE BEECHAM CORPORATION 2008-10-16 US disclosed
EP-1951250-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-08-06 EP disclosed
WO-2007062151-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255089-A1 Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives SHBG, ESR1, GPER1 PSMB1 1596/4885PSMB5 1938/4885PSMB2 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.